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The aim of the study was to assess the value of vascular endothelial growth factor
(VEGF) measurements in breast cancer patients with respect to recognized clinico-
pathological prognostic factors.
The study was conducted in 87 women with histologically confirmed breast cancer
who underwent surgical treatment and 37 healthy women. Vascular endothelial growth
factor concentration levels in the blood samples of patients were correlated with the size
of the primary tumor, lymph nodes in the armpit, cancer stage, histological type,
grading, multifocality, status of estrogen and progesterone receptors and HER-2 pro-
tein expression.
Statistical analysis did not show any correlation between concentrations of VEGF and
any of the selected parameters. The comparison of VEGF concentrations showed
a slightly raised level of VEGF in women with the disease as opposed to the healthy
subjects but the differences were not statistically significant (p = 0.472). Similar re-
sults were obtained for marker CEA (p = 0.09), while the level of Ca 15-3 in both
groups differed significantly (p < 0.001) reaching higher values in the patients with
diagnosed breast cancer.
Vascular endothelial growth factor concentrations in breast cancer patients do not
correlate with recognized clinicopathological prognostic factors and CEA and Ca 15-3
markers, which does not preclude the potential role of VEGF as an independent prog-
nostic factor.
Key words: vascular endothelial growth factor (VEGF), breast cancer, prognostic
factors.
Introduction
Breast cancer is the most common malignant neo-
plasm in women and leading cause of cancer-related
death in this group. The etiology of breast cancer re-
mains largely unknown. Risk factors associated with
the disease include female gender, advanced age,
menopause, breast cancer in the opposite breast, pos-
itive family history of breast cancer, BRCA1 and BRCA2
mutation, high socioeconomic status, childlessness, al-
cohol consumption and obesity. Despite enormous
progress that has taken place in diagnosing breast can-
cer, treatment results remain unsatisfactory. Therefore,
it seems necessary to seek new, independent prognos-
tic and predictive factors as well as optimal treatment
methods.
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In 1971, Folkman noticed that the growth of neo-
plasm is strictly linked to the process of angiogenesis,
i.e. the formation of new capillary vessels within the tu-
mor [1]. Progress of such pathological angiogenesis en-
ables local progress in the growth of the neoplasm and
contributes to the formation of distant metastasis [2].
A tumor without its own vessels, fed via diffusion, may
achieve a diameter of only 2-3 mm. Further stages of its
growth require production of substances that promote
the creation of a new network of capillary vessels that
will provide nutrition.
Angiogenesis, also called neovascularization, may oc-
cur in physiological conditions (wound healing) or in
a pathological state (inflammation, tumor). A number
of complex reactions lead to the formation of new blood
vessels from a preexisting vascular network. A signal
to start such process may be oxygen or nutrient short-
ages in tissue, as well as mutation of some suppressor
genes or oncogenes. A direct effect of the above process-
es is tumor-induced angiogenesis [3].
Neoangiogenesis involves the activity of cytokines,
enzymes, growth factors and adhesion molecules se-
creted by both tumor cells and stroma cells (fibroblasts,
neutrophils, macrophages, lymphocytes). They include
fibroblast growth factor (FGF), transforming growth
factor (TGF), interleukin-8 and prostaglandins [4]. At
present, the vascular endothelial growth factor (VEGF)
is considered to be the most important regulator in this
process. Identified by Ferrara in 1989 [5], it is also called
the vascular permeability factor (VPF) or vascu-
lotropin. Binding with the vascular endothelium re-
ceptors, VEGF induces the angiogenic phenotype re-
lated to constant stimulation of angiogenesis processes
[6, 7]. Vascular endothelial growth factor stimulates
the proliferation of endothelial cells in arteries, veins
and lymphatic vessels and affects their migration. By
disintegrating cell binding proteins, so called cadherins,
it loosens intracellular connections. New vessels are dif-
ferent from normal ones. They are twisted, widened or
denerved, have numerous arteriovascular fistulas, and
are hyperpermeable tortuous and irregularly shaped.
All of the above facilitates cancer cells passage to
the blood circulation system and is conducive to dis-
tant metastasis [8].
A high expression of VEGF has been found in many
kinds of tumors and in body fluids, as for example can-
cer of breast, large intestine, prostate, kidneys, and blad-
der.
The reports on the role of VEGF in breast cancer pa-
tients are not conclusive. Some research suggests
that a high level of VEGF may affect the biological ma-
lignancy of tumor, it may promote invasive growth and
metastases to regional lymph nodes and distant organs
[9, 10]. Some authors raise VEGF’s unfavorable prog-
nostic value, showing a correlation between a high lev-
el of VEGF and shorter survival rate [11-13]. Others
indicate a relationship between a high concentration
of this factor and poorer response to a systemic
chemo- and immunotherapy [14-16].
Objective of the study
The aim of the study was to assess the value of VEGF
measurements in breast cancer patients with respect
to recognized, clinicopathological prognostic factors.
Separating the group of patients with particularly poor
prognosis, even before surgical treatment, may affect
the change of the therapeutical strategy, which not only
has a cognitive value but is also of a clinical importance.
Material and methods
The study was conducted in 87 women with his-
tologically confirmed breast cancer who underwent ei-
ther radical surgery or breast conserving treatment in
2007-2009 at the Clinic of General, Oncological and
Gastroenterological Surgery of the University Hospi-
tal in Krakow.
Patients disqualified from the study were those:
• after breast cancer operations conducted outside
the Clinic,
• after chemo- or radiotherapy administered as in-
duction treatment outside the Clinic,
• with metastatic cancer (M1) and cancer recurrence
after primary treatment,
• with coexisting – in the past or in the present – ma-
lignant tumors in other organs,
• with diabetes, heart failure, lung diseases or ongo-
ing infection.
Blood samples were collected from the patients with
pre-invasive breast cancer, stage I, IIA and IIB inva-
sive cancers immediately before surgery, and from the pa-
tients with locally/regionally advanced (stage III)
breast cancer before initial hormone treatment or
chemotherapy. Serum VEGF levels were measured by
immunoenzymatic method using ELISA kit. Samples
for the blood clotting test were centrifugated and stored
at –20°C. The measurements were done at the De-
partment of Clinical Biochemistry of the Polish-Amer-
ican Institute of Pediatrics, Jagiellonian University Med-
ical College. Additionally, concentrations of CEA and
Ca 15-3 were tested. The control group consisted of 37
women subjected to screening tests at the Regional Out-
patient Clinic of Breast Diseases at the Clinic of Gen-
eral, Oncological and Gastroenterological Surgery
of the University Hospital in Cracow, in whom no
pathologies were found by imaging tests.
All histopathological tests were performed in
the Chair of Pathomorphology of the Jagiellonian Uni-
versity Medical College.
The results of histopathological tests were correlated
with the VEGF concentration levels, to assess the size
of the primary tumor, lymph nodes in the armpit, can-
cer stage according to the TNM classification, histo-
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logical type, grading, multifocality, status of estrogen
and progesterone receptors and HER-2 protein ex-
pression. Breast operations were also evaluated in terms
of radicality of surgery.
The associations between the VEGF concentration
and selected parameters were analyzed using the Pear-
son’s linear correlation coefficient and Mann-Whitney
test. The results were shown in the tables. A probability
value of ≤ 0.05 was considered statistically significant.
All statistical calculations were done using the STA-
TISTICA 3 program.
Results
The study consisted of 87 women with breast can-
cer, aged 32-85 (mean age 58 years). Statistical
analysis did not show any correlation between con-
centrations of VEGF and any of the selected parame-
ters, i.e. clinical stage of cancer, size of the primary tu-
mor, metastasis to regional lymph nodes, degree
of histological malignancy, angioinvasion, type of neo-
plasm, number of cancer foci, histological type or the ex-
pression of estrogen receptors, progesterone receptors
and HER-2 protein in tumor cells (Table I).
The comparison of VEGF concentrations in both
groups showed a slightly raised level of VEGF in women
with the disease as opposed to the healthy subjects but
the differences were not statistically significant (p =
= 0.472). Similar results were obtained for marker CEA
(p = 0.09), while the level of Ca 15-3 in both groups
differed significantly (p < 0.001) reaching clearly high-
er values in the patients with diagnosed breast cancer
(Table II).
Statistical analysis of obtained results did not reve-
al correlations between concentrations of VEGF vs.
Ca 15-3 (Fig. 1) and VEGF vs. CEA (Fig. 2).
Discussion
Identification of prognostic factors in cancer, also breast
cancer, helps to predict the probable course of tumor
growth, allows to select an optimal treatment, and con-
sequently enables longer survival. The introduction
of modern methods in pathomorphology, immuno-
histochemistry and molecular biology has contributed
to discovering new prognostic factors. The most im-
portant group comprises those whose prognostic val-
ue for breast cancer has been fully documented.
These include tumor size, condition of regional lymph
nodes, cancer stage in accordance with the pTNM clas-
sification, histological type, grading, status of estrogen
and progesterone receptors. Other factors that are test-
ed in the clinical studies include proliferation markers
(MIB1), HER2/c-erb, p53, occurrence of angioinvasion.
There are also factors whose prognostic value has not
yet been fully documented. These are VEGF, TGF-α
or cathepsin D [17].
As mentioned in the introduction, angiogenesis is
inevitable in the tumor growth and formation of lo-
coregional and systemic metastases [18-20]. The role
of VEGF in the angiogenesis is well recognized.
A high expression of VEGF is connected in most cas-
es with poor prognosis [21]. Learning in detail about
the phenomena related to the formation of patholog-
ical vasculature within the tumor and blocking VEGF
may therefore be an opportunity to stop tumor pro-
gression. Antiangiogenic therapy with the use of drugs
inhibiting angiogenesis is now intensively researched.
Despite promising preliminary results regarding be-
vacizumab – a monoclonal antibody that inhibits for-
mation of new blood vessels [22], there is still no ef-
fective method to cure breast cancer [23].
The results of the studies analyzing correlations be-
tween serum concentrations of VEGF in breast cancer
patients and the stage of cancer (pTNM), histological
type, grading, status of estrogen and progesterone re-
ceptors, and HER2 protein expression are inconsistent.
Some authors indicate the correlation between a high
concentration of VEGF, tumor size, and metastasis to
regional lymph nodes [24-26]. Significantly higher
VEGF concentrations were found in the patients
with metastatic cancer as compared with a group of pa-
tients with an advanced stage of local or regional can-
cer [27, 28]. Our results are significantly different. No
correlation was found between concentrations of VEGF
and the patient’s age, size of the primary tumor, metas-
tasis to lymph nodes, cancer stage according to
the TNM classification, grading, histological type as
well as the number of cancer foci. Similar results were
obtained by other authors. Granato, Gasparini, Toi, de
Paola found no correlation between VEGF concen-
trations and tumor size or metastasis to regional lymph
nodes [29-33] and no correlation was found in
the study of Sanack between VEGF levels and cancer
stage [34].
Among the prognostic factors in breast cancer are
estrogen and progesterone receptors which are positive
in 70-80% of tumors. Approximately 65-76% of can-
cers with a positive receptor status respond well to
the hormone suppression treatment. The other prog-
nostic factor is overexpression of human epidermal
growth factor receptor 2 (HER-2) occurring in 25-40%
of patients. Its incidence is usually connected with high-
er biological malignancy of the tumor and a more ag-
gressive course of the disease. It negatively affects re-
sponse to chemotherapy and hormone treatment,
despite the presence of receptors of estrogen and prog-
esterone on the surface of cancer cells [14-16]. Some
studies indicate a correlation between lack of hormone
receptors [35] and independently overexpression
of HER-2 [36, 37] in women with high serum con-
centrations of VEGF [36, 37].
Approximately 10-15% of all breast cancers are
triple-negative tumors that do not show expression of es-
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trogen, progesterone receptors and HER-2 protein. Such
configuration suggests limited options for adjuvant
treatment and, which could be observed in recent years,
it is related to poorer prognosis. Some authors reported
significantly higher concentrations of VEGF in triple
negative cancers [16, 38].
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Table I. VEGF concentrations depending on the tested histoclinical parameters
PARAMETER NO. VEGF [PG/ML] P
MEAN SD
Age < 50 years old 15 485.25 331.66 0.090
≥ 50 years old 72 330.26 330.43
Histological type Ductal 52 300.61 243.50 0.336
Lobular 22 270.86 248.98
Medullary 6 313.95 200.09 –
DCIS 2 279.80 147.76 –
Squamous cell 2 955.85 209.37 –
Mixed 3 352.46 267.41 –
Number of foci 1 61 317.46 263.44 0.299
Multi-focal 26 331.70 247.16
Grading 1 6 335.50 279.89 0.988
2 19 329.36 300.82
3 30 322.82 253.07
pT IS 2 197.95 58.90 –
1 52 277.77 209,77 0.439
2 26 346.13 285.50
3 2 1019.40 27.44 –
4 2 242.75 213.62 –
pN 0 53 306.96 245.95 0.788
1 12 222.60 137.30
2 12 301.13 212.61
3 10 442.89 391.02
Stage of cancer 0 3 279.80 147.76 –
I 34 275.01 216.64 0.394
IIA 26 328.17 262.17
IIB 1 126.10 –
IIIA 11 292.70 220.87 –
IIIB 2 242.75 213.62 –
IIIC 9 466.17 407.32 –
IV 1 233.40 –
Angioinvasion N 80 295.22 235.67 0.251
T 7 480.63 384.51
E receptor expression Negative 28 346.00 283.26 0.576
Positive 59 293.13 237.68
PG receptor expression Negative 38 335.29 274.78 0.599
Positive 49 290.64 235.40
HER 2 protein expression 0, 1+ 56 328.76 264.95 0.502
2+ 10 228.90 137.00
3+ 21 299.18 262.51
Radicality of resection R0 80 344.24 330.65 0.180
R1 7 330.65 386.22
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Meanwhile, our own research has not confirmed
the correlation between serum concentrations of VEGF
and expression of estrogen, progesterone receptors and
HER-2 in any of the possible configurations.
In view of our own observations and conflicting opin-
ions reported in other studies, it seems that concen-
tration measurements of VEGF may have a prognos-
tic value in breast cancer patients. We have not included
follow-up observations in the study, and therefore
the role of VEGF as an independent prognostic factor
in the analyzed group of patients cannot be excluded.
Conclusions
1. Vascular endothelial growth factor concentrations
in breast cancer patients do not correlate with
the clinical stage of neoplasm, the size of primary
tumor, metastasis to regional lymph nodes, degree
of histological malignancy, type of cancer, number
of cancer foci, histological type and expression of
estrogen receptors, progesterone receptors, and
HER-2 protein in the tumor cells.
2. No correlation was found between VEGF concen-
trations in breast cancer patients and CEA and Ca
15-3 markers.
3. Lack of correlation between the recognized prognostic
factors does not preclude a potential role of VEGF
as an independent prognostic factor in breast cancer.
4. The role of VEGF as a prognostic factor in breast
cancer and its applications in antiangiogenic ther-
apy requires further clinical research.
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